quazepam (Doral)

01/01/1982 - "The resuls confirm that quazepam in a dosage of 15 mg/night is safe and that it is more effective than placebo in treating insomnia in older patients."
02/01/1994 - "Insomnia improved after 1 night of treatment with 15 mg of quazepam. "
02/01/1994 - "Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients."
11/01/2019 - "Given the recent reintroduction of quazepam as a pharmacotherapeutic option, and the lack of head-to-head comparative trials against newer agents, the purpose of this review is to provide an update on distinguishing features of quazepam with regard to its pharmacology, pharmacokinetics, sleep efficacy and potential adverse effects compared to other agents used for insomnia."
02/01/1994 - "This open-label study in 2,813 outpatients provided evidence that quazepam reduces the complaints of insomnia in a difficult-to-treat psychiatric population after 1 night and after 7 nights of treatment. "

01/01/1982 - "Eleven patients, six receiving quazepam and five receiving the placebo, had adverse experiences, including ataxia, which was observed in two quazepam-treated and one place-bo-treated patient. "
01/01/1982 - "There were no reports of unexpected or serious adverse experiences, and quazepam did not cause ataxia or impairment of motor co-ordination in any patient."
01/01/1982 - "On the basis of the aforementioned studies, quazepam should be an effective hypnotic with less potential for ataxia, paradoxical excitation, and tolerance than flurazepam."
07/02/1984 - "Since halazepam and quazepam, like the triazolopyridazines, have behavioral effects in animals at doses much lower than those that cause ataxia, it is tempting to attribute this separation of pharmacologic activities to differential activity at subpopulations of benzodiazepine receptors. "
01/01/1982 - "In conscious, unrestrained squirrel monkeys and cats, quazepam produced sedation with less ataxia and less evidence of CNS stimulant action than flurazepam. "

10/01/1995 - "Although the exact location of the aneurysm in relation to the distal doral ring could not be determined by preoperative neuroradiological studies, a surgical repair of the aneurysm was indicated since both the aneurysm and the meningioma could be exposed in the same operative field. "

10/01/1995 - "Although the exact location of the aneurysm in relation to the distal doral ring could not be determined by preoperative neuroradiological studies, a surgical repair of the aneurysm was indicated since both the aneurysm and the meningioma could be exposed in the same operative field. "

12/01/2003 - "Blood samplings and evaluation of psychomotor function by the Digit Symbol Substitution Test and Stanford Sleepiness Scale were conducted up to 240 hours after quazepam dosing. "
08/01/2003 - "Blood samplings and evaluation of psychomotor function by the Digit Symbol Substitution Test and Stanford Sleepiness Scale were conducted up to 240 h after quazepam dosing. "
04/01/2003 - "Plasma concentrations of quazepam and its metabolite, 2-oxoquazepam and psychomotor function using the Digit Symbol Substitute Test (DSST), Stanford Sleepiness Scale (SSS) and Visual Analogue Scale were measured up to 48 h. "
12/01/2002 - "Quazepam was well tolerated, with no significant difference in the Stanford Sleepiness Scale between fasted and fed conditions. "
12/01/1982 - "Quazepam, 30 mg, induced frequent side effects related to sleepiness. "